L-THREO-3-(3,4-DIHYDROXYPHENYL)-N-METHYLSERINE IN ANHYDROUS CRYSTAL FORM
PURPOSE:The titled compound in an anhydrous crystal form, obtained by treating a hydrate, solvated substance, etc., of the titled compound with a heated solvent, useful for treating diseases in central nervous systems and having uniform quality and good stability as well as novel crystal structure....
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SASAKI FUJINORI ISHIKAWA MORIAKI SHIBA SHIGERU NAKAGAWA SUSUMU |
| description | PURPOSE:The titled compound in an anhydrous crystal form, obtained by treating a hydrate, solvated substance, etc., of the titled compound with a heated solvent, useful for treating diseases in central nervous systems and having uniform quality and good stability as well as novel crystal structure. CONSTITUTION:Hydrate, solvates substance, amorphous powder or L-threo-3-(3,4- dihydroxyphenyl)-N-methylserine or a mixture thereof is treated with a solvent, e.g. water, methanol or acetonitrile, heated to 40 deg.C-the boiling point of the solvent, preferably 50-70 deg.C for 15min-10hr to afford the aimed compound having a novel crystal structure. The above-mentioned compound has lattice spacings (d-value) and relative intensity (I) of an X-ray diffraction pattern [X ray source; CuKalpha (Ni filter used), output; 35kW 15mA, X-ray wavelength used; lambda=1.5418Angstrom ] shown in the table. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JPS62258347A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JPS62258347A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JPS62258347A3</originalsourceid><addsrcrecordid>eNrjZPDw0Q3xCHL11zXW1TDWMdF18fSIdAnyj4gM8HD1i_TR1PXT9XUN8Yj0CXYN8vRzVfD0U3D0AysJDVZwDooMDnH0UXDzD_LlYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyal5qSXxXgHBZkZGphbGJuaOxsSoAQD45y0p</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>L-THREO-3-(3,4-DIHYDROXYPHENYL)-N-METHYLSERINE IN ANHYDROUS CRYSTAL FORM</title><source>esp@cenet</source><creator>SASAKI FUJINORI ; ISHIKAWA MORIAKI ; SHIBA SHIGERU ; NAKAGAWA SUSUMU</creator><creatorcontrib>SASAKI FUJINORI ; ISHIKAWA MORIAKI ; SHIBA SHIGERU ; NAKAGAWA SUSUMU</creatorcontrib><description>PURPOSE:The titled compound in an anhydrous crystal form, obtained by treating a hydrate, solvated substance, etc., of the titled compound with a heated solvent, useful for treating diseases in central nervous systems and having uniform quality and good stability as well as novel crystal structure. CONSTITUTION:Hydrate, solvates substance, amorphous powder or L-threo-3-(3,4- dihydroxyphenyl)-N-methylserine or a mixture thereof is treated with a solvent, e.g. water, methanol or acetonitrile, heated to 40 deg.C-the boiling point of the solvent, preferably 50-70 deg.C for 15min-10hr to afford the aimed compound having a novel crystal structure. The above-mentioned compound has lattice spacings (d-value) and relative intensity (I) of an X-ray diffraction pattern [X ray source; CuKalpha (Ni filter used), output; 35kW 15mA, X-ray wavelength used; lambda=1.5418Angstrom ] shown in the table.</description><language>eng</language><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS ; CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>1987</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19871110&DB=EPODOC&CC=JP&NR=S62258347A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76516</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19871110&DB=EPODOC&CC=JP&NR=S62258347A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SASAKI FUJINORI</creatorcontrib><creatorcontrib>ISHIKAWA MORIAKI</creatorcontrib><creatorcontrib>SHIBA SHIGERU</creatorcontrib><creatorcontrib>NAKAGAWA SUSUMU</creatorcontrib><title>L-THREO-3-(3,4-DIHYDROXYPHENYL)-N-METHYLSERINE IN ANHYDROUS CRYSTAL FORM</title><description>PURPOSE:The titled compound in an anhydrous crystal form, obtained by treating a hydrate, solvated substance, etc., of the titled compound with a heated solvent, useful for treating diseases in central nervous systems and having uniform quality and good stability as well as novel crystal structure. CONSTITUTION:Hydrate, solvates substance, amorphous powder or L-threo-3-(3,4- dihydroxyphenyl)-N-methylserine or a mixture thereof is treated with a solvent, e.g. water, methanol or acetonitrile, heated to 40 deg.C-the boiling point of the solvent, preferably 50-70 deg.C for 15min-10hr to afford the aimed compound having a novel crystal structure. The above-mentioned compound has lattice spacings (d-value) and relative intensity (I) of an X-ray diffraction pattern [X ray source; CuKalpha (Ni filter used), output; 35kW 15mA, X-ray wavelength used; lambda=1.5418Angstrom ] shown in the table.</description><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS</subject><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1987</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZPDw0Q3xCHL11zXW1TDWMdF18fSIdAnyj4gM8HD1i_TR1PXT9XUN8Yj0CXYN8vRzVfD0U3D0AysJDVZwDooMDnH0UXDzD_LlYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyal5qSXxXgHBZkZGphbGJuaOxsSoAQD45y0p</recordid><startdate>19871110</startdate><enddate>19871110</enddate><creator>SASAKI FUJINORI</creator><creator>ISHIKAWA MORIAKI</creator><creator>SHIBA SHIGERU</creator><creator>NAKAGAWA SUSUMU</creator><scope>EVB</scope></search><sort><creationdate>19871110</creationdate><title>L-THREO-3-(3,4-DIHYDROXYPHENYL)-N-METHYLSERINE IN ANHYDROUS CRYSTAL FORM</title><author>SASAKI FUJINORI ; ISHIKAWA MORIAKI ; SHIBA SHIGERU ; NAKAGAWA SUSUMU</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JPS62258347A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>1987</creationdate><topic>ACYCLIC OR CARBOCYCLIC COMPOUNDS</topic><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SASAKI FUJINORI</creatorcontrib><creatorcontrib>ISHIKAWA MORIAKI</creatorcontrib><creatorcontrib>SHIBA SHIGERU</creatorcontrib><creatorcontrib>NAKAGAWA SUSUMU</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SASAKI FUJINORI</au><au>ISHIKAWA MORIAKI</au><au>SHIBA SHIGERU</au><au>NAKAGAWA SUSUMU</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>L-THREO-3-(3,4-DIHYDROXYPHENYL)-N-METHYLSERINE IN ANHYDROUS CRYSTAL FORM</title><date>1987-11-10</date><risdate>1987</risdate><abstract>PURPOSE:The titled compound in an anhydrous crystal form, obtained by treating a hydrate, solvated substance, etc., of the titled compound with a heated solvent, useful for treating diseases in central nervous systems and having uniform quality and good stability as well as novel crystal structure. CONSTITUTION:Hydrate, solvates substance, amorphous powder or L-threo-3-(3,4- dihydroxyphenyl)-N-methylserine or a mixture thereof is treated with a solvent, e.g. water, methanol or acetonitrile, heated to 40 deg.C-the boiling point of the solvent, preferably 50-70 deg.C for 15min-10hr to afford the aimed compound having a novel crystal structure. The above-mentioned compound has lattice spacings (d-value) and relative intensity (I) of an X-ray diffraction pattern [X ray source; CuKalpha (Ni filter used), output; 35kW 15mA, X-ray wavelength used; lambda=1.5418Angstrom ] shown in the table.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_JPS62258347A |
| source | esp@cenet |
| subjects | ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | L-THREO-3-(3,4-DIHYDROXYPHENYL)-N-METHYLSERINE IN ANHYDROUS CRYSTAL FORM |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T11%3A50%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SASAKI%20FUJINORI&rft.date=1987-11-10&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJPS62258347A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |